Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate
Benzinga Newsdesk 12 hours ago
NewsEarningsEarnings Beats
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent. This is a 6.67 percent decrease over losses of $(0.30) per share
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year.